Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
September 08 2022 - 9:15AM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company focused on Alzheimer’s disease, announced
today that it has been invited to present a corporate overview at
the H.C. Wainwright 24th Annual Global Investment Conference, being
held in New York.
Remi Barbier, President & CEO, will
participate in-person at this corporate event. Institutional
investors who are registered for this conference may log into
www.hcwevents.com to request a meeting with Cassava Sciences,
pending availability.
Event details
follow:Date: Tuesday, September
13thTime: 3:30pm to 4:00 Eastern
TimeWebcast: https://journey.ct.events/view/ffcd827b-9de0-4b05-a6fd-5ea79810a3ee
A live webcast will be available on the
“Investors” page of Cassava Sciences’ website,
www.CassavaSciences.com. An archived replay will be available for
90 days following the event.
About Cassava Sciences,
Inc.
Cassava Sciences Inc. is a clinical stage
biotechnology company based in Austin, Texas. Our mission is to
detect and treat neurodegenerative diseases, such as Alzheimer's
disease. Our novel science is based on stabilizing – but not
removing – a critical protein in the brain. We are currently
testing simufilam, our lead drug candidate for the proposed
treatment of Alzheimer's disease dementia, in a large Phase 3
clinical program under Special Protocol Assessments from the
FDA.
Eric Schoen
512-296-6757
eschoen@cassavasciences.com
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Apr 2023 to Apr 2024